Beta

Insight molecular diagnostics inc.IMDX.US Overview

US StockHealthcare
(No presentation for IMDX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

IMDX AI Insights

IMDX Overall Performance

IMDX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMDX Recent Performance

9.38%

Insight molecular diagnostics inc.

-1.10%

Avg of Sector

-0.49%

S&P500

IMDX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check IMDX's Trend

IMDX Key Information

IMDX Valuation Metrics

IMDX Profile

Price of IMDX

IMDX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMDX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
29.83
PB Ratio
196.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
56.97%
Net Margin
-1238.52%
Revenue Growth (YoY)
115.58%
Profit Growth (YoY)
286.93%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
29.83
PB Ratio
196.27
Price-to-FCF
-
Gross Margin
56.97%
Net Margin
-1238.52%
Revenue Growth (YoY)
115.58%
Profit Growth (YoY)
286.93%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IMDX's latest earnings report released?

    The most recent financial report for Insight molecular diagnostics inc. (IMDX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMDX's short-term business performance and financial health. For the latest updates on IMDX's earnings releases, visit this page regularly.

  • What is the operating profit of IMDX?

    According to the latest financial report, Insight molecular diagnostics inc. (IMDX) reported an Operating Profit of -23.44M with an Operating Margin of -2,057.51% this period, representing a growth of 30.31% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IMDX's revenue growth?

    In the latest financial report, Insight molecular diagnostics inc. (IMDX) announced revenue of 1.14M, with a Year-Over-Year growth rate of -23.35%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IMDX have?

    As of the end of the reporting period, Insight molecular diagnostics inc. (IMDX) had total debt of 3.5M, with a debt ratio of 0.14. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMDX have?

    At the end of the period, Insight molecular diagnostics inc. (IMDX) held Total Cash and Cash Equivalents of 12.31M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IMDX go with three margins increasing?

    In the latest report, Insight molecular diagnostics inc. (IMDX) did not achieve the “three margins increasing” benchmark, with a gross margin of 43.5%%, operating margin of -2,057.51%%, and net margin of -2,015.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IMDX's profit trajectory and future growth potential.

  • Is IMDX's EPS continuing to grow?

    According to the past four quarterly reports, Insight molecular diagnostics inc. (IMDX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.74. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMDX?

    Insight molecular diagnostics inc. (IMDX)'s Free Cash Flow (FCF) for the period is -7.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 26.24% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMDX?

    The latest valuation data shows Insight molecular diagnostics inc. (IMDX) has a Price-To-Earnings (PE) ratio of -2.63 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.